Ask for Sample/Enquiry and details report @ WMR
https://westernmarketresearch.com/sample-report/340678/Fondaparinux Market, By Types (Branded a#sample
WMR-Western Market Research has recently published a comprehensive and exclusive research report, which is an intelligent study covering all key segments. This research report provides breakthrough inputs and insights on market related factors like size, competition, trends, analysis, forecasts etc. The study encompasses primary and secondary data sources along with quantitative and qualitative practices thus assuring data accuracy.
The fondaparinux market was valued at USD 388.9 million by 2017, growing with 6.4% CAGR during the forecast period, 2018-2025
Ask for Sample/Enquiry and details report @ WMR
https://westernmarketresearch.com/market-report/340678/Fondaparinux Market, By Types (Branded a#inquiry
Fondaparinux is a molecule that is widely used in the pharmaceutical industry. This particular molecule is used as an anticoagulant (prevents the development of blood clots) in the healthcare industry. This drug due to its molecular structure as compared to regular heparin shows more efficacy. It is majorly used in medical conditions such as knee or hip replacement, deep vein thrombosis (DVT) and Pulmonary Embolism (PE). Arixtra, a type of Fondaparinux is the U.S. FDA approved drug to treat cases of pulmonary embolism especially in cases of DVT surgeries.
The benefits it offers over heparin is one of the reasons why this particular therapeutic has grown in this specific industry. One of the significant factors that will drive the market growth is the increase in the number of cases in knee and hip replacement. Since OECD Health Statistics 2017, stated that on an average the cases of hip replacement increased 30% from the year 2000 to 2015. Anticoagulants are also provided to geriatric populations due to a number of complications that could arise due to age-related diseases.
Click for BUY NOW and ask for lucrative Discount @ WMR
On contrary, there is a significant amount of uncertainty when it comes to government regulations regarding the use of fondaparinux, pull back the industry growth. Furthermore, this product is not very commonly promoted by doctors due to its associated side effects such as breathing issues, allergic reactions, numbness and muscle weakness.
The two major segments for this are generic and branded. Fondaparinux has a generic form of it available as an injectable blood thinner, popularly known as Arixtra. One of the most common End Uses for this product is the treatment for DVT and pulmonary thromboembolism. This product is quite highly priced, one of the major reasons for it is due to an extremely difficult manufacturing process the drug has to go through. It is a highly stringent and complex process. This is also a reason why fondaparinux is consumed with limitations.
To a great extent, an improvement in the R&D facilities can drastically change the way these products are manufactured. Governments across the globe are promoting the practice of using generic drugs from a regulatory standpoint. Countries such as France, Japan, and Spain have all adopted policies that promote the use of these generic drugs as there is better control over the pricing for these as compared to branded products. From an end use perspective generally the drug is used in hospitals, clinics, ambulances, home care set ups and diagnostic facilities across the healthcare set up.
An increase in the number of increased diseases, tumors, cardiovascular diseases in North Americas one of the reasons why North America is one of the leading users of the drug Fondaparinux. Illnesses such as haematological, neurological and CVD are increasingly predominant in North America. China is the second highest when it comes to consuming this product because the country is an evolving market from a pharmaceutical industry standpoint. It has been central when it comes to the manufacturing of various APIs from a global standpoint.
Key Vendor Takeaway
The key market players of this industry are GlaxoSmithKline Plc, Alchemia Ltd., Abbott Laboratories, Inc., Dr. Reddys Laboratories, Apotex, Inc., ScinoPharm Taiwan Ltd., Aurobindo Pharma and Lupin Pharmaceuticals. This is the consolidated industry, where handful companies capture significant revenue share.
Key players are engaged in new product introduction and merger and acquisitions to attract large customer base. For instance, in December 2017, Aurobindo Pharma received approval of Fondaparinux Sodium injection (5 mg/0.4 mL, 2.5 mg/0.5 mL, 10 mg/0.8 mL and 7.5 mg/0.6 mL single-dose prefilled syringes) from the US Food & Drug Administration (USFDA).
The market size and forecast for each segment and sub-segments has been considered as below:
Historical Year-2014 & 2016
Traders, Distributors, and Suppliers
Government and Regional Agencies
SCOPE OF THE REPORT
The scope of this report covers the market by its major segments, which include as follows:
MARKET, BY TYPE
MARKET, BY END USE
Ambulatory Surgical Centers
Home Care Settings
MARKET, BY REGION
Rest of Europe
Rest of APAC
Rest of the World
Middle East and Africa
Click to know more about product @ WMR
https://westernmarketresearch.com/market-report/340678/Fondaparinux Market, By Types (Branded a